期刊文献+

埃巴病毒潜伏膜蛋白的研究进展 被引量:1

Research Progress of Latent Membrane Protein Encoded by EBV
原文传递
导出
摘要 埃巴病毒(Epstein-Barr Virus, EBV)是一种在人群中感染率高达90%的γ-疱疹病毒,其感染宿主细胞后常以潜伏形式存在并伴随终生,在一定条件诱导下,由潜伏感染转化为裂解感染,导致多种恶性肿瘤的发生。LMP1和LMP2是EBV编码的重要潜伏膜蛋白,它们锚定于细胞膜脂筏区,通过与宿主细胞内多种信号传递分子如TRAF家族蛋白、Caspase家族蛋白和STAT家族等相互作用,参与细胞内多条信号转导通路,进而影响细胞迁移与凋亡,与淋巴组织增生性疾病和恶性肿瘤的发生有着密切联系。本文阐述了LMP1和LMP2的结构特征,在宿主细胞内的基因表达调控及参与信号转导途径的机制等,旨在推进EBV发病机理研究及疫苗的研发等科研进展。 Epstein-Barr virus(EBV) is a human γ-herpes virus which has an infection rate up to 90% in population. After infecting the host cells, EBV stays latent in the cells for life-long period. Under certain inducement, it will transforms from latent infection into lytic infection, which may trigger genesis of several types of malignant tumors. LMP1 and LMP2, the two key latent membrane proteins encoded by EBV, are anchored in the lipid raft region of the host cell membrane, interacting with signaling molecules, such as families of TRAF, Caspase and STAT. LMP1 and LMP2, involved in many signaling pathways, are considered closely related to lymphoproliferative diseases and tumorigenesis through cell migration and apoptosis. This article summarizes and discusses the structure/function of LMP1 and LMP2, focusing on their roles of gene expression regulation and signal transduction pathways in host cells, aiming to pave road for EBV pathogenesis research and related vaccine R&D.
作者 魏爱琪 王雯 王丽 王康康 金泰来 姬朝光 严汉池 WEI Ai-qi;WANG Wen;WANG Li;WANG Kang-kang;JIN Tai-lai;JI Chao-guang;YAN Han-chi(School of Life Sciences, Tianjin University, Tianjin, 300072, China)
出处 《现代生物医学进展》 CAS 2019年第8期1573-1577,共5页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(31470731) 天津大学自主创新基金项目(2014XST-0012 2015XRX-0026)
关键词 埃巴病毒 潜伏膜蛋白1 潜伏膜蛋白2 恶性肿瘤 Epstein-Barr Virus LMP1 LMP2 Malignant Tumor
  • 相关文献

参考文献1

二级参考文献37

  • 1Martin S, Nishimune A, Mellor JR, et al. SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature, 2007,447: 321-325.
  • 2Hay RT. SUMO: a history of modification. Mol Cell,2005,18: 1-12.
  • 3Yasugi T,Howley PM. Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9. Nucleic Acids Res, 1996, 24: 2005-2010.
  • 4Bettermann K,Benesch M, Weis S,et al. SUMOylation in carcinogenesis. Cancer Lett, 2012, 316: 113-125.
  • 5Johnson ES. Protein modification by SUMO. Annu RevBiochem, 2004,73: 355-382.
  • 6Johnson ES, Gupta AA. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell, 2001, 106: 735-744.
  • 7Geiss-Friedlander R,Melchior F. Concepts in sumoyla-tion: a decade on. Nat Rev Mol Cell Biol, 2007, 8: 947-956.
  • 8Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell, 2001, 107: 5-8.
  • 9Guo Y, Yang MC, Weissler JC, et al. Modulation of PLAGL2 transactivation activity by Ubc9 co-activation not SUMOylation. Biochem Biophys Res Commun, 2008,374:570-575.
  • 10Moschos SJ,Jukic DM, Athanassiou C, et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol, 2010, 41: 1286-1298.

共引文献2

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部